Compass Therapeutics Investor Presentation Deck
Overview of CTX-009
Bispecific antibody blocking DLL4 (Notch-1
ligand) and VEGF-A (soluble ligand)
➤
Does not lead to ADCC, Fc inactive
➤ Binds to its targets with 2:2 valency
At 10 mg/Kg, CTX-009 has approximately the
same VEGF-A capturing ability as bevacizumab
(Avastin)
The only DLL4 X VEGF bispecific that
demonstrated monotherapy activity in the clinic
in colorectal and gastric cancer
Durable responses in patients with
cholangiocarcinoma seen in Phase 1b study of
CTX-009 in combination with paclitaxel
COMPASS
THERAPEUTICS
(A)
(VEGF)
DLL4
Anti-VEGF MoAb
(Bevacizumab/Avastin)
Dual blockade of DLL4 and VEGF overcomes
VEGF resistance
VEGF/VEGF-R
signaling
(VEGF)
Decreased tumor
vessel formation;
Reduced tumor
growth
DLL4
(B)
8
ensin
Anti-DLL4 MoAb
DLL4-Notch
Signaling
Increased vessel
formation with poor
perfusion; Reduced
tumor growth
7View entire presentation